Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Oxatomide

Inhibits the release and actions of leukotrienes
 
BML-EI114-0010 10 mg 112.00 USD
 
BML-EI114-0050 50 mg 385.00 USD
Do you need bulk/larger quantities?
 
Suppresses PAF-induced bronchoconstriction in the guinea pig (ED50=0.9 mg/kg orally).

Product Specification

Formula:C27H30N4O
 
MW:426.6
 
CAS:60607-34-3
 
Purity:≥99% (HPLC)
 
Identity:Determined by IR, NMR and MS.
 
Appearance:White solid.
 
Solubility:Soluble in ethanol or DMSO.
 
Shipping:Ambient
 
Long Term Storage:Ambient
 
bml-ei114
Please mouse over
bml-ei114

Product Literature References

Suppression of PAF-induced bronchoconstriction in the guinea-pig by oxatomide: mechanism of action: F. P. Nijkamp, et al.; Naunyn-Schmeideberg's Arch. Pharmacol. 340, 111 (1989), Abstract;
Inhibitory effects of oxatomide on several activities of SRS-A and synthetic leukotrienes in guinea-pigs and rats: K. Ohmori, et al.; Arch. Int. Pharmacodyn. Ther. 275, 139 (1985), Abstract;
Oxatomide inhibits the release of bronchoconstrictor arachidonic acid metabolites (iLTC4 and PGD2) from rat mast cells and guinea-pig lung: Y. Kosaka, et al.; Agents Actions 21, 32 (1985), Abstract;
Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy: D. M. Richards, et al.; Drugs 27, 210 (1984), Abstract;

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Related Literature

Brochures
Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,